Presented encouraging interim data for anti-DLL3 T cell engager HPN328 from ongoing dose escalation clinical trial at the 2022 ASCO Annual Meeting
Portfolio prioritization and resource alignment strengthens support for the advancement of HPN328, HPN217 and HPN601
Read more at globenewswire.com